• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Savara announces $26.8 million private placement

Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales of the common stock and pre-funded warrants and a potential of up to $75 million if all milestone warrants are exercised. The private placement is led by Bain Capital Life Sciences, and Bain Capital’s Ricky Sun will join Savara’s board of directors.

Earlier this year, Savara initiated a Phase 2a study of its Molgradex inhaled GM-CSF for the treatment of nontuberculous mycobacterial (NTM) lung infections in cystic fibrosis patients. The company is also developing Molgradex for the treatment of NTM lung infections in non-CF patients and for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). The company’s AeroVanc inhaled vancomycin is in Phase 3 development.

In November 2019, Savara announced the appointment of former Director of the FDA’s Division of Pulmonary, Allergy, and Rheumatology Products in the Center for Drug Evaluation and Research (CDER), Badrul Chowdhury, as Chief Medical Officer.

Read the Savara press release.

Share

published on December 20, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews